Sugi Predict

Sugi Predict / Compounds / SCHEMBL2241314

SCHEMBL2241314

SCHEMBL2241314

O=C1C(Cl)=C(Nc2ccc(S(=O)(=O)Nc3ccccc3)cc2)C(=O)c2ccccc21

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 12/20 0.71
▸ MAPT P10636 11/20 0.71
▸ HTT P42858 10/20 0.71
▸ MEN1 O00255 10/20 0.71
▸ RAB9A P51151 8/20 0.71
▸ MAPK1 P28482 8/20 0.71
▸ NPSR1 Q6W5P4 8/20 0.71
▸ GAA P10253 6/20 0.71
▸ NPC1 O15118 5/20 0.71
▸ ATM Q13315 4/20 0.71
▸ LMNA P02545 3/20 0.71
▸ SMN1; SMN2 Q16637 3/20 0.71
▸ MITF O75030 2/20 0.71
▸ XBP1 P17861 1/20 0.71
▸ ALDH1A1 P00352 6/20 0.69
▸ HPGD P15428 3/20 0.69
▸ PSMB1 P20618 2/20 0.69
▸ PSMB5 P28074 2/20 0.69
▸ PSMB2 P49721 2/20 0.69
▸ CYP1A2 P05177 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2241087 0.91 MAPT (0.76) KMT2AMAPTHTTMEN1RAB9A
SCHEMBL2243450 0.87 ALDH1A1 (0.64) KMT2AMAPTHTTMEN1RAB9A
SCHEMBL20971703 0.87 ALDH1A1 (0.64) KMT2AMAPTHTTMEN1RAB9A
SCHEMBL2246284 0.86 MAPT (0.61) KMT2AMAPTHTTMEN1RAB9A
SCHEMBL29633261 0.84 MAPT (1.00) KMT2AMAPTHTTMEN1RAB9A
SCHEMBL6506683 0.84 MAPT (1.00) KMT2AMAPTHTTMEN1RAB9A
SCHEMBL2241338 0.83 ALDH1A1 (0.59) KMT2AMAPTHTTMEN1RAB9A
SCHEMBL2242640 0.83 ALDH1A1 (0.62) KMT2AMAPTHTTMEN1RAB9A
SCHEMBL29392404 0.82 ALDH1A1 (1.00) KMT2AMAPTHTTMEN1RAB9A
SCHEMBL2243581 0.82 ALDH1A1 (1.00) KMT2AMAPTHTTMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673910-B2 Proteasome inhibitors for selectively inducing apoptosis in cancer cells H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) 2014-03-18 — — US disclosed
US-8673910-B2 Proteasome inhibitors for selectively inducing apoptosis in cancer cells H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) 2014-03-18 — — US disclosed
US-20110201609-A1 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) 2011-08-18 — — US disclosed
US-20110201609-A1 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) 2011-08-18 — — US disclosed
WO-2010005534-A2 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2010-01-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201609-A1 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS PSMB7, PSMD7, PSMB6 KMT2A 2094/4885MAPT 4401/4885HTT 1280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.